Status:
COMPLETED
Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options
Lead Sponsor:
Pfizer
Conditions:
Febrile Neutropenia
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study was to define and classify antibacterial agents used in Turkey for patients with febrile neutropenia.
Eligibility Criteria
Inclusion
- Patients who are 18 years old and above.
- Patients who have undergone allogeneic/autologous or peripheral stem cell transplantation following induction or consolidation treatment due to acute hematological malignancy.
- Patients who have a neutrophil count below 500 cells per cubic millimeter (cells/mm\^3) or below 1000 cells/mm\^3 with an expectancy to rapidly decrease below 500 cells/mm\^3.
- Patients with a body temperature more than or equal to (≥)38.3 degrees Celsius (101 degrees Fahrenheit) on single oral measurement or detected ≥38.0 degrees Celsius for at least an hour and thus started on antibacterial treatment will be included in the trial.
Exclusion
- \- Patients who are pregnant or considering pregnancy.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT00945555
Start Date
June 1 2009
End Date
October 1 2010
Last Update
April 5 2017
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Kayseri, Turkey, Turkey (Türkiye)
2
Pfizer Investigational Site
Kocaeli, Turkey, Turkey (Türkiye)
3
Pfizer Investigational Site
Ankara, Turkey (Türkiye), 06500
4
Pfizer Investigational Site
Bursa, Turkey (Türkiye)